

December 19th, 2023

RE: Phase II study of the histone-deacetylase inhibitor ITF2357 in very high-risk relapsed/refractory Hodgkin's lymphoma patients

Dear Ethics Committee/Competent Authority,

We are writing to inform you of the voluntary, business-related decision of the sponsor, Italfarmaco SpA (from now Italfarmaco), to close the clinical trial with EudraCT number 2007-000049-36 on Hodgkin's lymphoma.

The trial was prematurely ended because insufficient evidence of efficacy and slow recruitment rate.


This decision was made after Italfarmaco performed a careful and due diligent analysis of the current study status.

Italfarmaco remains committed to meeting the needs of patients with Hodgkin's lymphoma and to ongoing research in the lymphoma therapeutic area.

If you have any questions or require additional information, please contact Serena Franciosi at the following email: s.franciosi@italfarmacogroup.com.

Asking for your kind relevant actions.

Kindest regards,



Serena Franciosi,
Clinical Operations Lead
Italfarmaco S.p.A.

Italfarmaco S.p.A.

Sede legale e stabilimento: 20126 Milano-Viale Fulvio Testi, 330 - Tel. 02.64.43.1 - Fax 02.64.43.46
Casella postale 11130 - 20100 Milano Isola

Direzione, Uffici e Centro ricerche: 20092 Cinisello Balsamo (MI) - Via dei Lavoratori, 54 - Tel. 02.64.43.1 - Fax 02.64.24.790
Capitale Sociale € 13.000.000 int.vers. - R.E.A. 273567 - Registro Imprese Milano - C.F. e P.IVA 00737420158